Fungal Endocarditis Observed Over an 8-Year Period and a Review of the Literature
Background Fungal endocarditis (FE) is a “modern” disease that is considered an emerging cause of infective endocarditis (IE). The most frequently identified fungal pathogens are Candida spp., which are responsible for up to two-thirds of all cases; the remaining cases are due to Aspergillus spp., H...
Saved in:
Published in | Mycopathologia (1975) Vol. 178; no. 1-2; pp. 37 - 51 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Dordrecht
Springer Netherlands
01.08.2014
Springer Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Fungal endocarditis (FE) is a “modern” disease that is considered an emerging cause of infective endocarditis (IE). The most frequently identified fungal pathogens are
Candida
spp., which are responsible for up to two-thirds of all cases; the remaining cases are due to
Aspergillus
spp.,
Histoplasma capsulatum
or, more rarely, other yeasts and moulds.
Objectives
To describe the prevalence, clinical characteristics and outcome of FE diagnosed in a single tertiary centre and review the literature concerning FE.
Design and setting
An 8-year retrospective review of the case records of patients attending a single Italian University Centre and diagnosed as having definite or probable IE as defined by the modified Duke criteria.
Results
Six patients were identified from 229 episodes of IE: five cases involved a prosthetic valve, and one a native valve of an intravenous drug user. Five cases were caused by
Candida
spp. (two by
C. albicans
, one each by
C. lusitaniae
,
C. dubliniensis
and
C. glabrata
) and one by
Aspergillus flavus
. Three patients were treated by means of surgery plus antifungal therapy; two received antifungal therapy alone. Three patients survived, but only the patient with
Aspergillus
endocarditis was followed up for a long time.
Conclusions
FE is difficult to diagnose but generally associated with healthcare infections. The optimal treatment is poorly characterised, and international collaborative studies are urgently needed to evaluate newer antifungal agents. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 0301-486X 1573-0832 |
DOI: | 10.1007/s11046-014-9754-4 |